Cargando…
Increased Risk for Developing Major Adverse Cardiovascular Events in Stented Chinese Patients Treated with Dual Antiplatelet Therapy after Concomitant Use of the Proton Pump Inhibitor
BACKGROUND: Some clinical studies have demonstrated that the proton pump inhibitor (PPI) could decrease clopidogrel platelet response and increase major adverse cardiovascular events (MACE) in white or black subjects. However, that remains to be determined in Chinese patients. In this study, we soug...
Autores principales: | Zou, Jian-Jun, Chen, Shao-Liang, Tan, Jie, Lin, Ling, Zhao, Ying-Ying, Xu, Hai-Mei, Lin, Song, Zhang, Juan, Fan, Hong-Wei, Xie, Hong-Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885647/ https://www.ncbi.nlm.nih.gov/pubmed/24416326 http://dx.doi.org/10.1371/journal.pone.0084985 |
Ejemplares similares
-
Clinical Outcomes of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis
por: Guo, Hongzhou, et al.
Publicado: (2021) -
Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents
por: Yoshikawa, Yusuke, et al.
Publicado: (2021) -
Antiplatelet agents and proton pump inhibitors – personalizing treatment
por: Lin, Eugene, et al.
Publicado: (2010) -
Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines
por: Saven, Hannah, et al.
Publicado: (2022) -
Concomitant Use of Antiplatelet Agents and Proton-Pump Inhibitors Increases the Risk of Adverse Cardiovascular Events: A Nationwide Population-Based Cohort Study Using Balanced Operational Definitions
por: Yang, Hee Gyu, et al.
Publicado: (2023)